![2-[[5-[4-(Dimethylsulfamoyl)phenyl]-8-methyl-2-oxo-1,6,7,9-tetrahydropyrrolo[3,2-H]isoquinolin-3-y…](https://static.cymitquimica.com/products/3D/img/VJA06359.png "Clique para ampliar")
2-[[5-[4-(Dimethylsulfamoyl)phenyl]-8-methyl-2-oxo-1,6,7,9-tetrahydropyrrolo[3,2-H]isoquinolin-3-ylidene]amino]oxy-4-hydroxybutanoic acid
CAS: 245063-59-6
Ref. 3D-VJA06359
| 5mg | A consultar | ||
| 10mg | A consultar | ||
| 25mg | A consultar | ||
| 50mg | A consultar | ||
| 100mg | A consultar |
Informação sobre produto
- 2-[[[5-[4-[(Dimethylamino)sulfonyl]phenyl]-1,2,6,7,8,9-hexahydro-8-methyl-2-oxo-3H-pyrrolo[3,2-h]isoquinolin-3-ylidene]amino]oxy]-4-hydroxybutanoic acid
- NS 1209
- (RS)-NS 1209
- Butanoic acid, 2-[[[5-[4-[(dimethylamino)sulfonyl]phenyl]-1,2,6,7,8,9-hexahydro-8-methyl-2-oxo-3H-pyrrolo[3,2-h]isoquinolin-3-ylidene]amino]oxy]-4-hydroxy-
Rimonabant is a drug that binds to the cannabinoid receptors in the brain. It has been shown to be effective for weight loss and smoking cessation. Rimonabant is metabolized by esterases, glucuronidases, glutathione reductase, cytochrome p450 enzymes, or conjugation with glucuronic acid. It has been shown to decrease food intake and body weight through activation of specific hypothalamic neurons that regulate appetite. Rimonabant's clinical development was halted in 2008 due to concerns about psychiatric side effects such as depression, anxiety, and suicidal thoughts.
Propriedades químicas
Consulta técnica sobre: 3D-VJA06359 2-[[5-[4-(Dimethylsulfamoyl)phenyl]-8-methyl-2-oxo-1,6,7,9-tetrahydropyrrolo[3,2-H]isoquinolin-3-ylidene]amino]oxy-4-hydroxybutanoic acid
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
